- Open Access
Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase
© Chang et al; licensee BioMed Central Ltd. 2011
- Received: 24 February 2011
- Accepted: 23 June 2011
- Published: 23 June 2011
Diabetic nephropathy (DN) has been recognized as the leading cause of end-stage renal disease. Resveratrol (RSV), a polyphenolic compound, has been indicated to possess an insulin-like property in diabetes. In the present study, we aimed to investigate the renoprotective effects of RSV and delineate its underlying mechanism in early-stage DN.
The protective effects of RSV on DN were evaluated in streptozotocin (STZ)-induced diabetic rats.
The plasma glucose, creatinine, and blood urea nitrogen were significantly elevated in STZ-induced diabetic rats. RSV treatment markedly ameliorated hyperglycemia and renal dysfunction in STZ-induced diabetic rats. The diabetes-induced superoxide anion and protein carbonyl levels were also significantly attenuated in RSV-treated diabetic kidney. The AMPK protein phosphorylation and expression levels were remarkably reduced in diabetic renal tissues. In contrast, RSV treatment significantly rescued the AMPK protein expression and phosphorylation compared to non-treated diabetic group. Additionally, hyperglycemia markedly enhanced renal production of proinflammatory cytokine IL-1β. RSV reduced IL-1β but increased TNF-α and IL-6 levels in the diabetic kidneys.
Our findings suggest that RSV protects against oxidative stress, exhibits concurrent proinflammation and anti-inflammation, and up-regulates AMPK expression and activation, which may contribute to its beneficial effects on the early stage of DN.
- Diabetic Nephropathy
- Renal Tissue
- Diabetic Kidney
- Blood Urea Nitrogen Level
Diabetes mellitus (DM), mainly characterized by recurrent hyperglycemia, had become one of the chronic disorders derived from insulin deficiency or resistance in the developed countries. As the high blood glucose level in diabetes persisted and progressed without appropriate medical care, relative secondary disorders involving atherosclerosis, retinopathy, nephropathy, neuropathy, stroke, and foot ulcer would individually develop with an insidious onset, which could eventually be life-threatening. Diabetic nephropathy (DN), the second most prevalent diabetes-associated complication inferior to cardiovascular disorders, impaired the renal function of DM patients and therefore cost appreciable medical labor and resource for DN management annually. Histologically featured by thickening of basement membrane, expansion and nodular aggregation of mesangial matrix (the Kimmelstiel-Wilson lesions) and sclerosis in glomeruli, DN could be multifactorial in the pathogenesis. In these risk factors, hyperglycemia was currently regarded as one of the leading causes in the progression of DN. Accumulating evidence also suggested the development of DN was associated with the activation of several stress-sensitive signal pathways, including nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) [1–4]. Additionally, it was reported that both oxidative stress [5–8] and proinflammatory cytokines [9, 10] detrimentally accelerated the pathological process of DN. Adenosine monophosphate-activated protein kinase (AMPK), a regulator of cellular energy homeostasis, was recently identified to play an important role in DN . Decreased phosphorylation of AMPK was contributed to hyperglycemia-associated renal enlargement. Further studies indicated that suppression of AMPK activity was linked with oxidative stress  and inflammatory response . Reversion of AMPK activity could ameliorate oxidative damage  and inflammation . Thus, attention has been drawn to the modulation of AMPK signal transduction to attenuate DM-affected renal dysfunction.
Resveratrol (trans-3,4',5-trihydroxyestilbene, RSV), one naturally existing polyphenolic compound rich in grapes and several plants, was characterized as a potently free radical scavenger and antioxidative agent. Besides, RSV was pronounced to possess both cardioprotective [16–18] and antidiabetic benefits [19, 20]. A vast majority of reports also supported that RSV displayed a hypoglycemic effect on DM animal models via AMPK stimulation [21–24]. In DN studies, RSV was proved to mitigate renal dysfunction and oxidative stress in type 1 diabetic rats [5, 25].
One recent research investigated the AMPK-stimulating effect of RSV on the early stage of DN . It was also reported that RSV did not remarkably alter the messenger RNA and protein levels of inflammation-regulatory cyclooxygenase (COX) in the diabetic rat kidneys . Additionally, RSV activated NF-κB in mesangial cells under a precondition of cytokine exposure . Therefore, it still required further survey to delineate the precise mechanisms of RSV action on DN.
Considering the hypoglycemic, antioxidative, inflammatory modulation and AMPK-up-regulating effects of RSV on type 1 DM, we designed this study to realize the therapeutic effects and associated mechanisms of RSV on streptozotocin (STZ)-induced DM rats. The oxidative stress, proinflammatory cytokines, and several cellular stress-activated signal pathways were simultaneously evaluated in diabetic rats. Our results show the renoprotective effects of RSV may contribute by its antioxidative and AMPK-up-regulating abilities and, to our interest, found that RSV significantly augmented inflammatory response in diabetic kidney by elevating several cytokines like tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), despite its ameliorative effect on IL-1β cytokine level in DN.
This survey was submitted to the rules written in the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996). Experiments were performed on male Long-Evans rats (6-7 weeks old, 220-250 g), maintained in the animal center of Chang Gung University within an environment-controlled room (ambient temperature of 25 ± 1°C and a light-dark period of 12 h) with free access to normal chow and water. The experimental animals were randomly assigned to two groups, the non-diabetic rats (control, CON) and STZ-induced diabetic rats (STZ-DM). In the diabetic group, male Long-Evans rats were fasted and anesthetized by intraperitoneal injection of pentobarbital at a dosage of 65 mg/kg. Freshly prepared STZ (65 mg/kg, Sigma-Aldrich, St. Louis, MO, USA) solution was then injected intravenously into the femoral vein of animals. The experimental rats with symptoms as polyphagia, polydipsia, and polyuria together with a blood glucose level above 300 mg/dl were considered diabetic. The blood glucose level was determined by the glucose oxidase method (chemistry analyzer; Auto Analyzer Quik-Lab, Ames, Spain). Two weeks after the onset of DM, the DM rats were further divided into three subgroups concomitantly treated with vehicle (STZ-DM), RSV 0.1 mg/kg (DM-R0.1) or RSV 1 mg/kg (DM-R1) for 7 consecutive days. RSV (Sigma-Aldrich, St. Louis, MO, USA) was suspended in 0.9% saline solution and administrated by oral gavage. At the end of RSV treatment course, the rats were euthanized and sacrificed. All the renal tissues and blood samples were preserved at -80°C.
Western blot analysis
Tissue lysates were extracted from renal tissues in accordance to previously published procedure with appropriate modifications . Briefly, dissected renal tissues were segmented into small pieces and pestled with liquid nitrogen. The grinding renal tissue samples were lysed with ice-cold lysis buffer containing 50 mM Tris-HCl (pH 7.4), 50 mM glycerophosphate, 20 mM sodium fluoride, 2 mM sodium orthovanadate, 2 mM Ethylenedinitrilotetraacetic acid (EDTA), 1 mM phenylmethanesulfonyl fluoride (PMSF), and 1% 2-mercaptoethanol. The homogenates were centrifuged at 12,000 g for 10 min at 4°C and the supernatants were isolated for Western blot preparation.
After protein determination, the samples were then separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 10 or 15% polyacrylamide denaturing gels and thus transferred onto polyvinylidene difluoride (PVDF) membranes, which were then probed with monoclonal antibodies with recommended dilution of manganese superoxide dismutase (MnSOD), copper-zinc SOD (CuZnSOD) (Upstate Biotechnology, Lake Placid, NY, USA), NF-κB, Erk, phospho-Erk (Thr202/Tyr204), p38, phospho-p38 (Thr180/Tyr182) (Chemicon, Temecula, CA, USA), JNK, phospho-JNK (Thr183/Tyr185) (Cell Signaling Technology, Cell Signaling, Boston, MA, USA), Akt, phospho-Akt (Thr308) (Santa Cruz), AMPK and phospho-AMPK (Thr172) (Chemicon), respectively. Following the incubation with appropriate secondary horseradish peroxidase (HRP)-conjugated IgG antibodies, the chemiluminescence was thus performed. The obtained protein bands were scanned and quantified with the aid of Image J software (NIH, Bethesda, MD, USA).
Oxidative stress and proinflammatory cytokines analysis
The renal production of superoxide anion was measured by modified lucigenin-enhanced chemiluminescence. The chemical specificity of this light-yielding reaction for superoxide anion has previously been described in detail . The extent of lipid peroxidation was determined using the modified thiobarbituric acid reactive substances (TBARS) method, which was also reported previously . The level of protein carbonyl group was measured by the 2,4-dinitrophenylhydrazine (DNPH) method with slight modification, as described previously . Furthermore, proinflammatory cytokines in renal tissues, including TNF-α, IL-1β and IL-6, were determined by using commercially acquired ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
To assess the renal pathology in the diabetic animal models, periodic acid-Schiff (PAS) stain was performed as described previously . In brief, the kidneys were immediately perfused with 4% paraffinparaformaldehyde after the decapitation of animals. The fixed renal tissues were paraffin-embedded and cross-sectioned into 2 μm thickness and periodic acid, Schiff's reagent and hematoxylin were further performed. After dehydration, the histopathological changes of stained glomeruli were observed and elucidated by the veteran pathologist with expert guidance.
All the biological measurements were determined using commercially available kits. The blood samples from experimental animals were obtained following by overnight fasting. Plasma glucose levels were evaluated on the basis of the glucose oxidase-catalyzed reaction (chemistry analyzer; Auto Analyzer Quik-Lab, Ames, Spain). Plasma insulin levels were measured by a sandwich enzyme-linked immunosorbent assay (ELISA) method (Mercodia, Uppsala, Sweden). Plasma cholesterol, triglyceride, creatinine, and blood urea nitrogen (BUN) levels were determined under the instructions provided by the manufacturer (Ransel kit, Randox, UK).
All values were expressed as mean ± standard error (SE). Following the performance by one-way analysis of variance (ANOVA), the difference of experimental data was analyzed by using Student t test. P < 0.05 was considered to be significant.
Effects of RSV on the body weight and biochemical parameters of the STZ-DM rats
The biochemical parameters of CON, STZ-DM, DM-R0.1 and DM-R1 rats
CON (n = 11)
STZ-DM (n = 7)
DM-R0.1 (n = 11)
DM-R1 (n = 15)
Body weight (g)
420.77 ± 8.88
280.29 ± 9.41*
330.77 ± 9.45*†
312.81 ± 10.55*†
Plasma glucose (mg/dl)
137.15 ± 10.86
566.33 ± 45.24*
444.17 ± 22.90*†
376.48 ± 35.56*†
Plasma insulin (μg/l)
2.00 ± 0.28
0.11 ± 0.06*
0.78 ± 0.25*†
0.86 ± 0.12*†
Plasma cholesterol (mg/dl)
67.30 ± 9.63
111.13 ± 16.98*
59.51 ± 7.16†
48.05 ± 5.64†
Plasma triglycerides (mg/dl)
88.27 ± 11.41
166.41 ± 35.43*
55.84 ± 7.47*†
63.52 ± 9.20†
Blood urea nitrogen (mg/dl)
16.27 ± 0.94
25.01 ± 3.90*
19.97 ± 1.52*
21.73 ± 1.72*
Plasma creatinine (mg/dl)
0.37 ± 0.04
0.59 ± 0.10*
0.41 ± 0.04†
0.48 ± 0.04
Effects of RSV on renal function and morphology in the STZ-DM rats
RSV ameliorated oxidative stress in the STZ-induced type 1 diabetic kidneys
RSV significantly decreased IL-1β cytokine level but enhanced TNF-α and IL-6 contents in the diabetic kidney without the involvement of NF-κB signaling pathway
The antidiabetic effect of RSV on renal tissues had no remarkable association with MAPK signaling pathway
RSV significantly attenuated AMPK signal reduction, with less attribution to Akt expression, in STZ-induced type 1 diabetic kidneys
A significant reduction in total and phosphorylated forms of AMPK expressions was observed in the kidneys of STZ-DM rats (Figure 4B). It was revealed that RSV treatment significantly increased AMPK phosphorylation and protein expression in the diabetic kidneys. Though there was no statistical significance, it was shown that an increased tendency of Akt phosphorylation and protein expression in the diabetic kidneys and RSV treatment augmented this tendency. In addition, the renal expression of phosphorylated Akt was also slightly elevated without significance in the STZ-DM group. Akt protein expression was significantly increased in RSV-treated diabetic rats when compared to normal control.
In the present study, we claimed that RSV significantly prevented loss of body weight, lowered plasma glucose and creatinine concentrations, and increased plasma insulin level, to moderate extents in the STZ-diabetic rats. Additionally, RSV remarkably alleviated oxidative stress and prevented AMPK protein down-regulation may contribute to its renoprotective effects in the diabetic rats. Interestingly, our experimental results further revealed that RSV significantly reduced the levels of IL-1β but elevated that of TNF-α and IL-6 in the diabetic kidney. To our knowledge, this is the first report to investigate the concurrently suppressive and stimulating effects of RSV on proinflammatory cytokines in the renal tissues of diabetes in vivo.
It has been shown that hyperglycemia promoted oxidative stress in nephritic tissues, eventually leading to renal injury in diabetes. Augmentation of free radicals and impairment of key antioxidant enzymes were believed to contribute to the development of DN. The ameliorative effects of RSV on hyperglycemia-associated oxidative stress were widely recognized . RSV was proved to possess an insulin-like property in vivo . Further, there was increasing evidence implicating that RSV alleviated oxidative stress in a variety of hyperglycemia-affected tissues, including renal , neuron , vascular endothelial , and pancreatic β cells . One recent study indicated that RSV prevented lipid peroxidation and increased glutathione contents and activities of SOD and catalase in STZ-induced diabetic kidneys . It was also reported that RSV decreased the generation of reactive oxygen species (ROS) and nitric oxide in high glucose-exposed porcine renal proximal tubular cells . However, our results suggested that RSV partially attenuated hyperglycemia-associated oxidative injury mediated by reduction of superoxide anion and protein carbonyl levels, but did not alleviate lipid peroxidation in renal tissues.
Attraction has been drawn to the correlation between inflammatory activity and diabetic complications. There was accumulating evidence indicating that renal inflammation played a key role in the pathogenesis of DN. it was demonstrated that diabetes increased proinflammatory cytokines including TNF-α, IL-1β and IL-6 in the circulating , renal production [37, 38], and urinary excretion . Our results revealed excessive renal production of IL-1β in the early stage of DN. Administration of RSV significantly inhibited IL-1β elevation in the diabetic kidneys. RSV treatment, however, elevated TNF-α and IL-6 levels in the renal tissues of the diabetic group. Recently, several researches have proved that RSV did not suppress but augmented signals responsible for inflammation in the renal tissues of diabetes. Gene and protein expressions of COX, one prostaglandin synthase mainly activated in certain inflammatory conditions, were not suppressed by RSV treatment in the renal tissues of diabetic rodents . Instead, RSV enhanced NF-κB activity in the renal tubular and mesangial cells exposed to cytokine mixtures . Although these reports indicated the proinflammatory potential of RSV which was similar to our experimental results, they were contrastive to previous studies identifying the anti-inflammatory property of RSV in diabetes. We showed that RSV modulated proinfammatory cytokines but unaffected NF-κB signals, implying a possibility that RSV modulates inflammation mediated by other existing cascades against cellular stress in DN. The effects of RSV on renal inflammation in DM remain to be further elucidated.
Under physiological circumstances, the signaling regulations of cellular energy like insulin cascades were predominated by both Akt and AMPK. It was demonstrated that suppression of AMPK was interposed by hyperglycemia and elevated Akt activity . In addition, a recent study revealed that reduced phosphorylation of AMPK appeared to be reversed under RSV treatment in the diabetic kidney . Our finding suggested that RSV prevented renal AMPK dephosphorylation and protein down-regulation in insulin-deficient diabetic rats. It was observed a tendency of increased Akt phosphorylation in the diabetic kidney, without any remarkable influence after RSV treatment. Since AMPK was newly identified as a modulating factor in diabetes-induced renal injury, RSV treatment may play a novel role as a therapeutic agent by prevention of AMPK dephosphorylation and protein down-regulation in early-stage DN.
In conclusion, the present study provides evidence that RSV reduced plasma glucose and creatinine, oxidative stress, proinflammatory cytokines and up-regulated AMPK proteins in diabetes which may contribute to its renoprotective effects in the early stage of DN. Interestingly, RSV decreased proinflammatory cytokine IL-1β but elevated TNF-α and IL-6 levels in renal tissues of STZ-induced diabetic rats. If and how RSV influences renal inflammation still remains controversial. RSV also prevented AMPK protein dephosphorylation and down-regulation in the insulin-deficient diabetic kidney. These findings suggest that RSV may serve as one useful new therapeutic agent in the early stage of DN.
This work was financially supported by research grants from Chang Gung Memorial Hospital (CMRPD 180191) and the National Science Council (NSC 97-2320-B-182-022-MY3) of Taiwan to Dr. Li-Man Hung.
- Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000, 404 (6779): 787-90. 10.1038/35008121.View ArticlePubMedGoogle Scholar
- Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414 (6865): 813-20. 10.1038/414813a.View ArticlePubMedGoogle Scholar
- Joseph LE, Ira DG, Betty AM, Gerold MG: Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes. Endocr Rev. 2002, 23 (5): 599-622. 10.1210/er.2001-0039.View ArticleGoogle Scholar
- Chen L, Zhang J, Zhang Y, Wang Y, Wang B: Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats. Inflamm Res. 2008, 57 (5): 199-204. 10.1007/s00011-006-6190-z.View ArticlePubMedGoogle Scholar
- Dhaunsi GS, Bitar MS: Antioxidants attenuate diabetes-induced activation of peroxisomal functions in the rat kidney. J Biomed Sci. 2004, 11 (5): 566-70. 10.1007/BF02256120.View ArticlePubMedGoogle Scholar
- Araujo M, Welch WJ: Oxidative stress and nitric oxide in kidney function. Curr Opin Nephrol Hypertens. 2006, 15 (1): 72-7. 10.1097/01.mnh.0000191912.65281.e9.View ArticlePubMedGoogle Scholar
- Fujii H, Kono K, Nakai K, Goto S, Komaba H, Hamada Y, Shinohara M, Kitazawa R, Kitazawa S, Fukagawa M: Oxidative and nitrosative stress and progression of diabetic nephropathy in type 2 diabetes. Am J Nephrol. 2010, 31 (4): 342-52. 10.1159/000297290.View ArticlePubMedGoogle Scholar
- Xiao H, Li Y, Qi J, Wang H, Liu K: Peroxynitrite plays a key role in glomerular lesions in diabetic rats. J Nephrol. 2009, 22 (6): 800-8.PubMedGoogle Scholar
- Vlassara H, Torreggiani M, Post JB, Zheng F, Uribarri J, Striker GE: Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int Suppl. 2009, S3-11. 114Google Scholar
- Wu J, Mei C, Vlassara H, Striker GE, Zheng F: Oxidative stress-induced JNK activation contributes to proinflammatory phenotype of aging diabetic mesangial cells. Am J Physiol Renal Physiol. 2009, 297 (6): F1622-31. 10.1152/ajprenal.00078.2009.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, Kasinath BS: A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol. 2007, 292 (2): F617-27.View ArticlePubMedGoogle Scholar
- Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu C, Viollet B, Yan D, Zou MH: AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res. 2010, 106 (6): 1117-28. 10.1161/CIRCRESAHA.109.212530.PubMed CentralView ArticlePubMedGoogle Scholar
- Ko HJ, Zhang Z, Jung DY, Jun JY, Ma Z, Jones KE, Chan SY, Kim JK: Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes. 2009, 58 (11): 2536-46. 10.2337/db08-1361.PubMed CentralView ArticlePubMedGoogle Scholar
- Ceolotto G, Gallo A, Papparella I, Franco L, Murphy E, Iori E, Pagnin E, Fadini GP, Albiero M, Semplicini A, Avogaro A: Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler Thromb Vasc Biol. 2007, 27 (12): 2627-33. 10.1161/ATVBAHA.107.155762.View ArticlePubMedGoogle Scholar
- Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, Kim WS, Kim JB: Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 2009, 296 (4): E955-64. 10.1152/ajpendo.90599.2008.View ArticlePubMedGoogle Scholar
- Hung LM, Su MJ, Chen JK: Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic Biol Med. 2004, 36 (6): 774-81. 10.1016/j.freeradbiomed.2003.12.016.View ArticlePubMedGoogle Scholar
- Lin JF, Lin SM, Chih CL, Nien MW, Su HH, Hu BR, Huang SS, Tsai SK: Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci. 2008, 83 (9-10): 313-7. 10.1016/j.lfs.2008.06.016.View ArticlePubMedGoogle Scholar
- Chan AY, Dolinsky VW, Soltys CL, Viollet B, Baksh S, Light PE, Dyck JR: Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem. 2008, 283 (35): 24194-201. 10.1074/jbc.M802869200.PubMed CentralView ArticlePubMedGoogle Scholar
- Su HC, Hung LM, Chen JK: Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab. 2006, 290 (6): E1339-46. 10.1152/ajpendo.00487.2005.View ArticlePubMedGoogle Scholar
- Chi TC, Chen WP, Chi TL, Kuo TF, Lee SS, Cheng JT, Su MJ: Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci. 2007, 80 (18): 1713-20. 10.1016/j.lfs.2007.02.002.View ArticlePubMedGoogle Scholar
- Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA: Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006, 444 (7117): 337-42. 10.1038/nature05354.View ArticlePubMedGoogle Scholar
- Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA: Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes. 2006, 55 (8): 2180-91. 10.2337/db05-1188.View ArticlePubMedGoogle Scholar
- Penumathsa SV, Thirunavukkarasu M, Zhan L, Maulik G, Menon VP, Bagchi D, Maulik N: Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med. 2008, 12 (6A): 2350-61. 10.1111/j.1582-4934.2008.00251.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH: AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010, 59 (3): 554-63. 10.2337/db09-0482.PubMed CentralView ArticlePubMedGoogle Scholar
- Sharma S, Anjaneyulu M, Kulkarni SK, Chopra K: Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology. 2006, 76 (2): 69-75. 10.1159/000089720.View ArticlePubMedGoogle Scholar
- Ding DF, You N, Wu XM, Xu JR, Hu AP, Ye XL, Zhu Q, Jiang XQ, Miao H, Liu C, Lu YB: Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK. Am J Nephrol. 2010, 31 (4): 363-74. 10.1159/000300388.View ArticlePubMedGoogle Scholar
- Yar AS, Menevse S, Alp E, Helvacioglu F, Take G: The effects of resveratrol on cyclooxygenase-1 and cyclooxygenase-2 mRNA and protein levels in diabetic rat kidneys. Mol Biol Rep. 2010, 37 (5): 2323-31. 10.1007/s11033-009-9737-6.View ArticlePubMedGoogle Scholar
- Uchida Y, Yamazaki H, Watanabe S, Hayakawa K, Meng Y, Hiramatsu N, Kasai A, Yamauchi K, Yao J, Kitamura M: Enhancement of NF-kappaB activity by resveratrol in cytokine-exposed mesangial cells. Clin Exp Immunol. 2005, 142 (1): 76-83. 10.1111/j.1365-2249.2005.02895.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Hung LM, Su MJ, Chu WK, Chiao CW, Chan WF, Chen JK: The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy. Br J Pharmacol. 2002, 135 (7): 1627-33. 10.1038/sj.bjp.0704637.PubMed CentralView ArticlePubMedGoogle Scholar
- Calabrese V, Mancuso C, Sapienza M, Puleo E, Calafato S, Cornelius C, Finocchiaro M, Mangiameli A, Di Mauro M, Stella AM, Castellino P: Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones. 2007, 12 (4): 299-306. 10.1379/CSC-270.1.PubMed CentralView ArticlePubMedGoogle Scholar
- Schmitz A, Gundersen HJ, Osterby R: Glomerular morphology by light microscopy in non-insulin-dependent diabetes mellitus. Lack of glomerular hypertrophy. Diabetes. 1988, 37 (1): 38-43. 10.2337/diabetes.37.1.38.View ArticlePubMedGoogle Scholar
- Kumar A, Kaundal RK, Iyer S, Sharma SS: Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci. 2007, 80 (13): 1236-44. 10.1016/j.lfs.2006.12.036.View ArticlePubMedGoogle Scholar
- Ungvari Z, Labinskyy N, Mukhopadhyay P, Pinto JT, Bagi Z, Ballabh P, Zhang C, Pacher P, Csiszar A: Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol. 2009, 297 (5): H1876-81. 10.1152/ajpheart.00375.2009.PubMed CentralView ArticlePubMedGoogle Scholar
- Palsamy P, Subramanian S: Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol. 2010, 224 (2): 423-32. 10.1002/jcp.22138.View ArticlePubMedGoogle Scholar
- Fujii H, Yokozawa T, Kim YA, Tohda C, Nonaka G: Protective effect of grape seed polyphenols against high glucose-induced oxidative stress. Biosci Biotechnol Biochem. 2006, 70 (9): 2104-11. 10.1271/bbb.60053.View ArticlePubMedGoogle Scholar
- Kaul K, Hodgkinson A, Tarr JM, Kohner EM, Chibber R: Is inflammation a common retinal-renal-nerve pathogenic link in diabetes?. Curr Diabetes Rev. 2010, 6 (5): 294-303. 10.2174/157339910793360851.View ArticlePubMedGoogle Scholar
- Huang J, Siragy HM: Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression. Endocrinology. 2009, 150 (12): 5557-65. 10.1210/en.2009-0442.PubMed CentralView ArticlePubMedGoogle Scholar
- Matavelli LC, Huang J, Siragy HM: (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin Exp Pharmacol Physiol. 2010, 37 (3): 277-82. 10.1111/j.1440-1681.2009.05292.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Bondar' IA, Klimontov VV, Nadeev AP: Urinary excretion of proinflammatory cytokines and transforming growth factor beta at early stages of diabetic nephropathy. Ter Arkh. 2008, 80 (1): 52-6.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.